# RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

> **NCT06328777** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cabaletta Bio** · enrollment: 12 (estimated)

## Conditions studied

- Systemic Sclerosis
- Scleroderma

## Interventions

- **BIOLOGICAL:** CABA-201

## Key facts

- **NCT ID:** NCT06328777
- **Lead sponsor:** Cabaletta Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-02
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328777, "RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis". Retrieved via MORVS 2026-10-31 from https://api.morvs.ai/clinical/NCT06328777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*